Skip to main content

Agilent to Use Caliper LabChips for Clinical Diagnostic Apps

NEW YORK, July 12 (GenomeWeb News) - Caliper Life Sciences has granted Agilent Technologies a non-exclusive license to use a "majority" of Caliper's microfluidics patent estate to develop clinical diagnostic applications on several Agilent instrument platforms, the companies said today.


Specifically, Agilent will incorporate the LabChip microfluidics technology into its 2100 Bioanalyzer, 5100 Automated Lab-on-a-Chip, and future instrument platforms.


Separately, the companies said that Agilent will use Caliper as its exclusive supplier of planar LabChip products for the 2100 Bioanalyzer and future products for the next five years.


Under the terms of the agreement, Agilent will pay an upfront undisclosed licensing fee to Caliper, as well as royalties on future sales of diagnostic LabChip products. Additional financial terms of the agreement were not disclosed.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.